Researchers to trial experimental breast cancer drug with lung cancer patients

Posted by pt91 at Mar 12, 2014 12:41 PM |
Leicester cancer expert leads investigation of potential treatment for most common cause of cancer death

Cancer researchers led by the University of Leicester are investigating whether an experimental drug originally designed to treat breast cancer will benefit patients with advanced lung cancer.

The drug, called olaparib – a type of treatment called a PARP inhibitor – will be given after chemotherapy to patients with non-small cell lung cancer (NSCLC) to see if it delays the growth of their tumour.

Professor Dean Fennell (pictured) of our Department of Cancer Studies and Molecular Medicine is the chief investigator for the trial, in which patients will first have chemotherapy and those who respond will then be given either olaparib or a placebo. They will be closely monitored to see how long the drug prevents their tumour from growing.

Olaparib is also currently being tested in phase III trials for ovarian and stomach cancers.